This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
BMS is trying to gain ground in lung cancer via the CheckMate -227 trial combining Opdivo with its CTLA4 inhibitor Yervoy (ipilimumab), and at AACR reported that the duo almost doubled
The US regulator has given the green light to PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) as an initial treatment for advanced renal cell carcinoma (RCC) patients on
line RCC, which is due to generate results in 2019 but will also come up against combination therapies from immuno-oncology rivals, not least Opdivo and BMS’CTLA4 inhibitor Yervoy (ipilimumab)
Meanwhile, in February the CHECKMATE-227 trial of BMS’combination of Opdivo and Yervoy (ipilimumab) showed a significant benefit on PFS in first-line NSCLC patients with high TMB, regardless of
That means for now, PD1/PD-L1 inhibitors as monotherapy, or combined with chemotherapy or CTLA4 drugs like BMS’Yervoy (ipilimumab) “may end up continuing to be the dominant regimens”.
Meanwhile, a similar approach has been trialled by Bristol-Myers Squibb with Its PD-1 inhibitor Opdivo (nivolumab) and CTLA4 blocker Yervoy (ipilimumab).
More from news
Approximately 9 fully matching, plus 143 partially matching documents found.
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
drug Yervoy (ipilimumab).
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary clinical
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
Bristol-Myers-Squibb redefines Melanoma treatment standards. In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...